vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and RADIANT LOGISTICS, INC (RLGT). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $232.1M, roughly 1.1× RADIANT LOGISTICS, INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 2.3%, a 8.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -12.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $11.6M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 12.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Radiant Logistics, Inc. is a leading third-party logistics provider offering end-to-end supply chain solutions, domestic and international freight forwarding, warehousing, and last-mile delivery services. It primarily serves North American markets, with key client segments including retail, manufacturing, e-commerce, and industrial sectors, helping businesses optimize logistics workflows and cut operational costs.
ANIP vs RLGT — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $232.1M |
| Net Profit | $27.5M | $5.3M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 3.2% |
| Net Margin | 11.1% | 2.3% |
| Revenue YoY | 29.6% | -12.3% |
| Net Profit YoY | 367.5% | -18.0% |
| EPS (diluted) | $1.14 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $232.1M | ||
| Q3 25 | $227.8M | $226.7M | ||
| Q2 25 | $211.4M | $220.6M | ||
| Q1 25 | $197.1M | $214.0M | ||
| Q4 24 | $190.6M | $264.5M | ||
| Q3 24 | $148.3M | $203.6M | ||
| Q2 24 | $138.0M | $206.0M | ||
| Q1 24 | $137.4M | $184.6M |
| Q4 25 | $27.5M | $5.3M | ||
| Q3 25 | $26.6M | $1.3M | ||
| Q2 25 | $8.5M | $4.9M | ||
| Q1 25 | $15.7M | $2.5M | ||
| Q4 24 | $-10.3M | $6.5M | ||
| Q3 24 | $-24.2M | $3.4M | ||
| Q2 24 | $-2.3M | $4.8M | ||
| Q1 24 | $18.2M | $-703.0K |
| Q4 25 | 14.1% | 3.2% | ||
| Q3 25 | 15.9% | 0.9% | ||
| Q2 25 | 6.6% | 2.4% | ||
| Q1 25 | 13.3% | 1.6% | ||
| Q4 24 | -2.3% | 3.3% | ||
| Q3 24 | -13.8% | 1.9% | ||
| Q2 24 | 3.7% | 2.4% | ||
| Q1 24 | 14.8% | -0.5% |
| Q4 25 | 11.1% | 2.3% | ||
| Q3 25 | 11.7% | 0.6% | ||
| Q2 25 | 4.0% | 2.2% | ||
| Q1 25 | 8.0% | 1.2% | ||
| Q4 24 | -5.4% | 2.4% | ||
| Q3 24 | -16.3% | 1.7% | ||
| Q2 24 | -1.7% | 2.3% | ||
| Q1 24 | 13.2% | -0.4% |
| Q4 25 | $1.14 | $0.11 | ||
| Q3 25 | $1.13 | $0.03 | ||
| Q2 25 | $0.36 | $0.10 | ||
| Q1 25 | $0.69 | $0.05 | ||
| Q4 24 | $-0.45 | $0.13 | ||
| Q3 24 | $-1.27 | $0.07 | ||
| Q2 24 | $-0.14 | $0.11 | ||
| Q1 24 | $0.82 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $31.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $229.8M |
| Total Assets | $1.4B | $439.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $31.9M | ||
| Q3 25 | $262.6M | $28.1M | ||
| Q2 25 | $217.8M | $22.9M | ||
| Q1 25 | $149.8M | $19.0M | ||
| Q4 24 | $144.9M | $19.9M | ||
| Q3 24 | $145.0M | $10.4M | ||
| Q2 24 | $240.1M | $24.9M | ||
| Q1 24 | $228.6M | $31.2M |
| Q4 25 | $540.7M | $229.8M | ||
| Q3 25 | $505.8M | $225.7M | ||
| Q2 25 | $436.8M | $226.0M | ||
| Q1 25 | $418.6M | $218.2M | ||
| Q4 24 | $403.7M | $214.4M | ||
| Q3 24 | $405.9M | $212.4M | ||
| Q2 24 | $455.8M | $209.4M | ||
| Q1 24 | $452.0M | $206.0M |
| Q4 25 | $1.4B | $439.4M | ||
| Q3 25 | $1.4B | $445.3M | ||
| Q2 25 | $1.3B | $426.8M | ||
| Q1 25 | $1.3B | $414.5M | ||
| Q4 24 | $1.3B | $386.8M | ||
| Q3 24 | $1.3B | $375.3M | ||
| Q2 24 | $920.8M | $371.2M | ||
| Q1 24 | $914.5M | $364.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $12.4M |
| Free Cash FlowOCF − Capex | $29.1M | $11.6M |
| FCF MarginFCF / Revenue | 11.8% | 5.0% |
| Capex IntensityCapex / Revenue | 0.5% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.33× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $8.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $12.4M | ||
| Q3 25 | $44.1M | $2.5M | ||
| Q2 25 | $75.8M | $3.1M | ||
| Q1 25 | $35.0M | $-5.7M | ||
| Q4 24 | $15.9M | $15.7M | ||
| Q3 24 | $12.5M | $205.0K | ||
| Q2 24 | $17.4M | $1.3M | ||
| Q1 24 | $18.3M | $3.9M |
| Q4 25 | $29.1M | $11.6M | ||
| Q3 25 | $38.0M | $977.0K | ||
| Q2 25 | $71.8M | $2.2M | ||
| Q1 25 | $32.5M | $-6.4M | ||
| Q4 24 | $13.5M | $14.1M | ||
| Q3 24 | $7.7M | $-1.9M | ||
| Q2 24 | $13.0M | $-185.0K | ||
| Q1 24 | $13.7M | $1.8M |
| Q4 25 | 11.8% | 5.0% | ||
| Q3 25 | 16.7% | 0.4% | ||
| Q2 25 | 34.0% | 1.0% | ||
| Q1 25 | 16.5% | -3.0% | ||
| Q4 24 | 7.1% | 5.3% | ||
| Q3 24 | 5.2% | -0.9% | ||
| Q2 24 | 9.4% | -0.1% | ||
| Q1 24 | 10.0% | 1.0% |
| Q4 25 | 0.5% | 0.3% | ||
| Q3 25 | 2.7% | 0.7% | ||
| Q2 25 | 1.9% | 0.4% | ||
| Q1 25 | 1.3% | 0.3% | ||
| Q4 24 | 1.3% | 0.6% | ||
| Q3 24 | 3.2% | 1.0% | ||
| Q2 24 | 3.2% | 0.7% | ||
| Q1 24 | 3.3% | 1.2% |
| Q4 25 | 1.10× | 2.33× | ||
| Q3 25 | 1.66× | 1.90× | ||
| Q2 25 | 8.87× | 0.63× | ||
| Q1 25 | 2.23× | -2.26× | ||
| Q4 24 | — | 2.43× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.26× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RLGT
| Transferred Over Time | $201.2M | 87% |
| Other | $25.0M | 11% |
| Value Added Services | $4.2M | 2% |
| Transferred At Point In Time | $1.8M | 1% |
